A Phase 2/3 interventional study of Sirolimus in Pulmonary Fibrosis, COVID-19 Pneumonia and Long COVID, sponsored by University of Chicago. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.
Sponsored by University of Chicago · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.
Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 37th largest by planned enrollment of the 90 interventional ones that give a count, is one of 11 that started in 2021, is one of 2 in phase 2/3, reaches primary completion later than 12 of the 38 other live ones, and was the 91st registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
PureTech · Sites in United States, Canada
Ages 40+
Peter Caravan · Sites in United States
Ages 18–80
University of Wisconsin, Madison · Sites in United States
Ages 18+
Cedars-Sinai Medical Center · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 48 · Phase 3 17 · Phase 4 3
First in 1978; this study’s year is marked. 11 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is close to the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 50 across the 90 interventional studies, 200 across the 37 observational. Of the 76 that completed or were terminated, 37 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 128 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 2 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Pulmonary Fibrosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04948203Phase 3University of ChicagoAssessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | 2026-12 |
| NCT00515567University of ChicagoExplanted Lung Tissues With Pulmonary Fibrosis | 2026-12 |
| NCT06567717Cedars-Sinai Medical CenterZinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis | 2027-01 |
| NCT04964115Vanderbilt University Medical CenterPost Acute Sequelae of COVID-19 | 2027-05-31 |
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
Add all 9 to your calendar (.ics) → With an account.
Among the 128 studies in Pulmonary Fibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.
Hospitalized patients with a diagnosis of COVID-19 pneumonia will be referred to the study team for potential recruitment. Initial screening will take place using the existing medical record and in collaboration with the treating team. The study consists of 3 randomly assigned arms of varying dosages of the study drug
All procedures, with the exception of drug dosing and option sample analysis, align with the subject's standard of care. Prior to initiating study drug, the subject's standard of care labs, imaging and oxygen requirements will be reviewed.
Sirolimus will be administered as an oral medication. Subjects who are discharged prior to receiving 14 days of study drug will be provided with enough study drug to finish at home.
On-study evaluation includes measurement of vital signs and laboratory studies before and after a patient has received sirolimus while inpatient. As part of routine care, subjects will be seen daily while in the hospital and will be monitored through blood tests for general health as well as renal function. Vital signs will be monitored daily while in the hospital, physical exams, assessment of COVID-19, and CT scans or chest x-rays as necessary for routine care.
Subjects will return to clinic at 12 weeks for routine lab work and imaging as a part of study follow-up and will be assessed for pulmonary fibrosis at this time.
Additionally, University of Chicago Medicine patients will have the option to allow investigators to use leftovers from tubes of blood drawn for clinical tests that would otherwise be discarded. This will apply to any blood collected during that respective hospital stay as well as up to 1 year after study enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject will take Sirolimus 0.5mg orally daily for 14 days.
Drug: Sirolimus
Subject will take Sirolimus 1mg orally daily for 14 days.
Drug: Sirolimus
Subject will take Sirolimus 2mg orally daily for 14 days.
Drug: Sirolimus
Triangular-shaped tablet
Also known as: RAPAMUNE
Prevalence of Pulmonary Fibrosis as evidenced by CT scan
Number of patients with \>10% pulmonary fibrosis on chest CT
Time frame: 12 Weeks
10% Threshold for Pulmonary Fibrosis evidenced by CT scan
Number of patients with \>10% pulmonary fibrosis on chest CT
Time frame: 12 Weeks
Qualitative Fibrotic markers on chest CT
Number of patients with the presence or absence of chest CT imaging markers of fibrosis
Time frame: 12 Weeks
Quantitative Fibrosis Score on chest CT
Quantitative Fibrosis Score on chest CT
Time frame: 12 Weeks
Duration of Increased Supplemental Oxygen from Baseline
Number of days over which the participant requires supplemental oxygen in excess over baseline supplemental oxygen requirement.
Time frame: 84 Days
Pulmonary Function Test impairment
Number of subjects with the presence of abnormal indices of lung function tests
Time frame: 12 Weeks
Safety - Rate of Liver Function Test abnormalities
Number of patients in a study arm who develop severe impairment of liver function tests exceeding three times the upper limit of normal
Time frame: 12 Weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus